- Home
- MUFG vs AMGN Comparison
MUFG vs AMGN Comparison
Compare MUFG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUFG
- AMGN
- Stock Information
- Founded
- MUFG 1880
- AMGN 1980
- Country
- MUFG Japan
- AMGN United States
- Employees
- MUFG N/A
- AMGN N/A
- Industry
- MUFG Commercial Banks
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MUFG Finance
- AMGN Health Care
- Exchange
- MUFG Nasdaq
- AMGN Nasdaq
- Market Cap
- MUFG 141.2B
- AMGN 156.2B
- IPO Year
- MUFG 2001
- AMGN N/A
- Fundamental
- Price
- MUFG $12.54
- AMGN $265.86
- Analyst Decision
- MUFG
- AMGN Buy
- Analyst Count
- MUFG 0
- AMGN 19
- Target Price
- MUFG N/A
- AMGN $324.37
- AVG Volume (30 Days)
- MUFG 5.7M
- AMGN 2.7M
- Earning Date
- MUFG 05-19-2025
- AMGN 05-01-2025
- Dividend Yield
- MUFG 3.03%
- AMGN 3.58%
- EPS Growth
- MUFG 37.26
- AMGN 56.16
- EPS
- MUFG 0.96
- AMGN 10.94
- Revenue
- MUFG $39,430,543,625.00
- AMGN $34,126,000,000.00
- Revenue This Year
- MUFG $70.59
- AMGN $7.19
- Revenue Next Year
- MUFG $0.12
- AMGN $2.37
- P/E Ratio
- MUFG $12.69
- AMGN $24.29
- Revenue Growth
- MUFG 69.42
- AMGN 15.56
- 52 Week Low
- MUFG $8.75
- AMGN $253.30
- 52 Week High
- MUFG $15.03
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- MUFG 53.09
- AMGN 34.80
- Support Level
- MUFG $12.24
- AMGN $268.81
- Resistance Level
- MUFG $12.47
- AMGN $291.61
- Average True Range (ATR)
- MUFG 0.16
- AMGN 7.54
- MACD
- MUFG 0.07
- AMGN -0.76
- Stochastic Oscillator
- MUFG 77.55
- AMGN 0.76
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.